Trial Filter

BETA

An intelligent search tool for clinical trials

Sign In
Back|NCT03391778Recruiting
Official Title

Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies

Phase
Phase 1
Sponsor
Adaptimmune
Enrollment
250
Timeline
Apr 2018 → Apr 2032
About This Study

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Eligibility Criteria

Inclusion Criteria

  • 1Participants who have received at least one dose of ADP adoptive cell therapy agent.
  • 2Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
  • 3Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
  • 4Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • 5The investigator is responsible for review of medical history.
  • 6Capable of giving signed informed consent.

Exclusion Criteria

  • 1\- None

Locations

24 sites participating in this study

Emory University School of Medicine

Atlanta, Georgia 30322

Recruiting

Melinda Yushak

ADP Investigational Site

Baltimore, Maryland 21201

Recruiting

Aaron Rapoport

National Cancer Institute - Center for Cancer Research

Bethesda, Maryland 20892

Completed
Data sourced from ClinicalTrials.govView on ClinicalTrials.gov →